y0news
AnalyticsDigestsSourcesTopicsRSSAICrypto

#eli-lilly News & Analysis

7 articles tagged with #eli-lilly. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.

7 articles
AIBullishFortune Crypto · Jun 117/10
🧠

Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it

Abridge, a $5.3 billion ambient AI startup backed by NVIDIA and Eli Lilly, is expanding beyond clinical note-taking into billing, drug trials, and real-time insurance claims processing. The expansion positions Abridge as a comprehensive operating system for healthcare operations, leveraging AI to automate administrative and clinical workflows across the medical industry.

Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it
🏢 Nvidia
AI × CryptoNeutralBlockonomi · Jun 206/10
🤖

ARK Invest Exits Roku and Robinhood: Here’s What Cathie Wood Is Buying Instead

ARK Invest, led by Cathie Wood, has exited significant positions in Roku and Robinhood, reallocating capital into Eli Lilly, Coinbase, and Block. This portfolio reshuffle reflects Wood's strategic shift toward healthcare innovation and cryptocurrency-adjacent fintech companies amid changing market conditions.

GeneralBullishBlockonomi · Jun 96/10
📰

AlzeCure Pharma (ALZCUR) Stock Jumps Over 300% on Eli Lilly Partnership

AlzeCure Pharma's stock surged 301% following a licensing deal with pharmaceutical giant Eli Lilly valued at over $1 billion for the Alzheimer's drug candidate ACD680. This partnership represents significant validation of AlzeCure's therapeutic approach and demonstrates major pharma's confidence in the company's pipeline.

GeneralBullishBlockonomi · Jun 86/10
📰

Eli Lilly (LLY) Stock Surges 4% Following Breakthrough Sleep Apnea Trial Results

Eli Lilly's stock gained 4% after Phase 3 trial data showed its drug retatrutide reduced sleep apnea by 60% and knee pain by 73%, demonstrating superior efficacy compared to competitor Novo Nordisk's offerings. This breakthrough in metabolic and inflammatory disease treatment positions Lilly as a leading contender in the high-growth GLP-1 and obesity-related pharmaceutical market.

GeneralBullishBlockonomi · Jun 56/10
📰

Eli Lilly (LLY) Stock Surges 4% After CVS Reverses Zepbound Coverage Decision

Eli Lilly's stock rose 4% following CVS Caremark's decision to reverse its prior exclusion of Zepbound, now covering both Eli Lilly's weight-loss drugs alongside competitor Novo Nordisk's products. This policy reversal signals expanding insurance coverage for GLP-1 medications and validates Eli Lilly's competitive position in the rapidly growing obesity treatment market.

GeneralNeutralBlockonomi · Jun 245/10
📰

Eli Lilly Finalizes $7.8B Centessa (CNTA) Acquisition with 183% Stock Rally

Eli Lilly completed its $7.8 billion acquisition of Centessa Pharmaceuticals at $38 per share, with the biotech company's stock experiencing a 183% surge before delisting. The transaction marks a significant consolidation in the pharmaceutical sector and represents a major exit event for Centessa shareholders.

GeneralBullishBlockonomi · Jun 85/10
📰

Monday’s Stock Winners: Eli Lilly (LLY), Nurix (NRIX), and Broadcom (AVGO) Rally

Three major stocks rallied on Monday: Eli Lilly gained on positive Foundayo obesity trial results, Nurix surged 38% following a $2.3 billion acquisition deal with Roche, and AI chip stocks like Broadcom recovered from Friday's market decline. These gains reflect renewed investor confidence in healthcare innovation and semiconductor strength.